SCHEMBL5742434

SCHEMBL5742434

Cc1ccc(S(=O)(=O)Nc2ccc3c(=O)c4c(sc3c2)CC(C)(C)CC4)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
HTT P42858 2/20 0.45
ALDH1A1 P00352 7/20 0.43
MAPT P10636 3/20 0.43
USP2 O75604 1/20 0.43
HSD17B10 Q99714 1/20 0.43
THRB P10828 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
GPR55 Q9Y2T6 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
PKM P14618 2/20 0.41
ALOX12 P18054 1/20 0.41
BRD4 O60885 2/20 0.40
PTPRC P08575 1/20 0.40
ESR1 P03372 1/20 0.39
CYP19A1 P11511 1/20 0.39
FFAR4 Q5NUL3 1/20 0.39
DPP4 P27487 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5739271 0.91 ALDH1A1 (0.42) LMNASMN1; SMN2ALDH1A1THRBGPR55
SCHEMBL5740233 0.73 LIMK1 (0.40) SMN1; SMN2ALDH1A1MAPTESR1
SCHEMBL5738947 0.73 LIMK1 (0.35) MAPTHSD17B10ESR1
SCHEMBL5740408 0.71 SLC34A2 (0.35) GPR55ESR1
SCHEMBL5741839 0.71 RXRA (0.37) SMN1; SMN2
SCHEMBL5740798 0.71 LIMK1 (0.33)
SCHEMBL5739197 0.69 LIMK1 (0.34) LMNAMAPT
SCHEMBL5740635 0.69 TNIK (0.41) LMNASMN1; SMN2HTTALDH1A1MAPT
SCHEMBL5741287 0.68 LIMK1 (0.36)
SCHEMBL6502371 0.68 PRMT5 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1406891-B1 THIOCHROMENONES USED TO COMBAT PAINFUL CONDITIONS AND NEURODEGENERATIVE DISEASES BAYER HEALTHCARE AG (DE) 2006-03-22 EP disclosed
US-20050009820-A1 Thiochromenones used to combat painful conditions and neurodegenerative diseases BAYER HEALTHCARE AG (DE) 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009820-A1 Thiochromenones used to combat painful conditions and neurodegenerative diseases HTT, HMOX1, SNCA LMNA 3784/4885SMN1; SMN2 87/4885HTT 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.